Goto Y - Search Results

1

Comparison of the Efficacy of EGFR Tyrosine Kinase Inhibitors Erlotinib and Low-dose Osimertinib on a PC-9-GFP EGFR Mutant Non-small-cell Lung Cancer Growing in the Brain of Nude Mice.

Katsuya Y, Miyake K, Higuchi T, Oshiro H, Sugisawa N, Singh SR, Goto Y, Zhao M, Hoffman RM. Katsuya Y, et al. Among authors: goto y. In Vivo. 2020 May-Jun;34(3):1027-1030. doi: 10.21873/invivo.11871. In Vivo. 2020. PMID: 32354888 Free PMC article.

2

Early stage non-small cell lung cancer patients need brain imaging regardless of symptoms.

Ando T, Kage H, Saito M, Amano Y, Goto Y, Nakajima J, Nagase T. Ando T, et al. Among authors: goto y. Int J Clin Oncol. 2018 Aug;23(4):641-646. doi: 10.1007/s10147-018-1254-y. Epub 2018 Feb 26. Int J Clin Oncol. 2018. PMID: 29484515

3

Mean platelet volume and lymphocyte-to-monocyte ratio are associated with shorter progression-free survival in EGFR-mutant lung adenocarcinoma treated by EGFR tyrosine kinase inhibitor.

Watanabe K, Yasumoto A, Amano Y, Kage H, Goto Y, Yatomi Y, Takai D, Nagase T. Watanabe K, et al. Among authors: goto y. PLoS One. 2018 Sep 7;13(9):e0203625. doi: 10.1371/journal.pone.0203625. eCollection 2018. PLoS One. 2018. PMID: 30192878 Free PMC article.

4

Mixed response to osimertinib and the beneficial effects of additional local therapy.

Shinno Y, Goto Y, Sato J, Morita R, Matsumoto Y, Murakami S, Kanda S, Horinouchi H, Fujiwara Y, Yamamoto N, Ohe Y. Shinno Y, et al. Among authors: goto y. Thorac Cancer. 2019 Apr;10(4):738-743. doi: 10.1111/1759-7714.12991. Epub 2019 Feb 8. Thorac Cancer. 2019. PMID: 30735003 Free PMC article.

5

Malignant pleural effusion as a predictor of the efficacy of anti-PD-1 antibody in patients with non-small cell lung cancer.

Shibaki R, Murakami S, Shinno Y, Matsumoto Y, Goto Y, Kanda S, Horinouchi H, Fujiwara Y, Motoi N, Yamamoto N, Ohe Y. Shibaki R, et al. Among authors: goto y. Thorac Cancer. 2019 Apr;10(4):815-822. doi: 10.1111/1759-7714.13004. Epub 2019 Feb 14. Thorac Cancer. 2019. PMID: 30762312 Free PMC article.

6

Efficacy of subsequent docetaxel +/- ramucirumab and S-1 after nivolumab for patients with advanced non-small cell lung cancer.

Tamura N, Horinouchi H, Sekine K, Matsumoto Y, Murakami S, Goto Y, Kanda S, Fujiwara Y, Yamamoto N, Ohe Y. Tamura N, et al. Among authors: goto y. Thorac Cancer. 2019 May;10(5):1141-1148. doi: 10.1111/1759-7714.13055. Epub 2019 Mar 26. Thorac Cancer. 2019. PMID: 30913364 Free PMC article.

7

The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV.

Akamatsu H, Ninomiya K, Kenmotsu H, Morise M, Daga H, Goto Y, Kozuki T, Miura S, Sasaki T, Tamiya A, Teraoka S, Tsubata Y, Yoshioka H, Hattori Y, Imamura CK, Katsuya Y, Matsui R, Minegishi Y, Mizugaki H, Nosaki K, Okuma Y, Sakamoto S, Sone T, Tanaka K, Umemura S, Yamanaka T, Amano S, Hasegawa K, Morita S, Nakajima K, Maemondo M, Seto T, Yamamoto N. Akamatsu H, et al. Among authors: goto y. Int J Clin Oncol. 2019 Jul;24(7):731-770. doi: 10.1007/s10147-019-01431-z. Epub 2019 May 2. Int J Clin Oncol. 2019. PMID: 31049758 Free PMC article.

8

Difference in central nerve system metastasis during gefitinib or erlotinib therapy in patients with EGFR-mutated non-small cell lung cancer: a retrospective study.

Yoshida K, Kanda S, Shiraishi H, Goto K, Itahashi K, Goto Y, Horinouchi H, Fujiwara Y, Nokihara H, Yamamoto N, Ohe Y. Yoshida K, et al. Among authors: goto y, goto k. J Thorac Dis. 2019 Apr;11(4):1347-1354. doi: 10.21037/jtd.2019.03.61. J Thorac Dis. 2019. PMID: 31179076 Free PMC article.

9

Differences Between the East and the West in Managing Advanced-Stage Non-small Cell Lung Cancer.

Lee VHF, Mok TSK, Goto Y, Hsue VCC, Yang L, Jiang Y, Leung DKC, Lau KS, Tse PY. Lee VHF, et al. Among authors: goto y. Clin Oncol (R Coll Radiol). 2020 Jan;32(1):e1-e9. doi: 10.1016/j.clon.2019.07.014. Epub 2019 Jul 30. Clin Oncol (R Coll Radiol). 2020. PMID: 31375307

10

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.

Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih JY, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M; RELAY Study Investigators. Nakagawa K, et al. Lancet Oncol. 2019 Dec;20(12):1655-1669. doi: 10.1016/S1470-2045(19)30634-5. Epub 2019 Oct 4. Lancet Oncol. 2019. PMID: 31591063 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,658 results

Search Page

Filters